CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure.
AC133 Antigen
/ genetics
Antimetabolites, Antineoplastic
/ pharmacology
Cell Line, Tumor
Colon
/ metabolism
Drug Combinations
Drug Synergism
Fluorouracil
/ pharmacology
Gene Expression
Humans
Hyaluronan Receptors
/ genetics
Inhibitory Concentration 50
Neoplastic Stem Cells
/ drug effects
Pyrrolidines
/ pharmacology
Spheroids, Cellular
/ drug effects
Thymidine Kinase
/ genetics
Thymine
/ pharmacology
Trifluridine
/ pharmacology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 10 2019
16 10 2019
Historique:
received:
19
02
2019
accepted:
12
09
2019
entrez:
18
10
2019
pubmed:
18
10
2019
medline:
3
11
2020
Statut:
epublish
Résumé
Cancer stem cells (CSCs) are involved in metastatic colorectal cancer recurrence, but no effective therapy targeting these cells is currently available. Because trifluridine (FTD)/tipiracil therapy is used for refractory colorectal cancer, we sought to determine whether FTD is effective against CSC-like cells. CD44
Identifiants
pubmed: 31619711
doi: 10.1038/s41598-019-50968-6
pii: 10.1038/s41598-019-50968-6
pmc: PMC6795793
doi:
Substances chimiques
AC133 Antigen
0
Antimetabolites, Antineoplastic
0
CD44 protein, human
0
Drug Combinations
0
Hyaluronan Receptors
0
PROM1 protein, human
0
Pyrrolidines
0
Thymidine Kinase
EC 2.7.1.21
thymidine kinase 1
EC 2.7.1.21
tipiracil
NGO10K751P
Thymine
QR26YLT7LT
Trifluridine
RMW9V5RW38
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14861Références
Lancet Oncol. 2012 Oct;13(10):993-1001
pubmed: 22951287
Cell Stem Cell. 2014 Dec 4;15(6):692-705
pubmed: 25479747
Mol Cells. 2006 Jun 30;21(3):343-55
pubmed: 16819296
Cancer Res. 2009 Mar 1;69(5):1951-7
pubmed: 19244128
Chin J Cancer. 2010 Sep;29(9):810-5
pubmed: 20800023
Cancer. 2017 Apr 15;123(8):1303-1312
pubmed: 28117883
Int J Oncol. 2015;46(6):2327-34
pubmed: 25901475
Nature. 2007 Jan 4;445(7123):106-10
pubmed: 17122772
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Cancer Cell Int. 2018 Sep 10;18:135
pubmed: 30214377
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Cancer Invest. 2009 Oct;27(8):844-50
pubmed: 19626493
Nature. 2007 Jan 4;445(7123):111-5
pubmed: 17122771
Lancet Oncol. 2018 Nov;19(11):1437-1448
pubmed: 30355453
PLoS One. 2013;8(2):e56380
pubmed: 23409180
Biochem Pharmacol. 2000 May 15;59(10):1227-36
pubmed: 10736423
Pathol Int. 2012 Feb;62(2):112-9
pubmed: 22243781
Ther Adv Med Oncol. 2015 Nov;7(6):340-56
pubmed: 26557901
Cancer Cell. 2011 Mar 8;19(3):387-400
pubmed: 21397861
Oncotarget. 2016 Feb 16;7(7):7657-66
pubmed: 26840024
Oncogene. 2008 Mar 13;27(12):1749-58
pubmed: 17891174
Oncotarget. 2017 Sep 8;8(44):77734-77751
pubmed: 29100421
Sci Rep. 2016 May 03;6:25286
pubmed: 27137226
Cell Stem Cell. 2007 Oct 11;1(4):389-402
pubmed: 18371377
Lancet Oncol. 2019 Jun;20(6):849-861
pubmed: 31003911
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050